Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
Do you recommend the use of diazoxide for the management of reactive hypoglycemia in patients who have not responded to acarbose or dietary modifications?
Related Questions
Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?
Does injectable semaglutide have a higher glucose-lowering efficiency than oral semaglutide?
Is it safe to use acarbose in patients with advanced chronic kidney disease?
In patients using a tandem insulin pump on auto-mode/Control-IQ, would decreasing the basal settings on the profile actually reduce the delivered hourly insulin dose or is that only relevant if they switch to manual mode?
Do you recommend avoiding the use of GLP-1 agonists in patients with a history of suicidal thoughts, given recent evidence showing an association with increased risks of psychiatric disorders, including depression and suicidal behavior?
When would you consider switching a patient with insulin-requiring Type 2 DM to an automated insulin delivery system?
What is the recommended approach to treating severe constipation in patients on GLP1 R agonist therapy?
Do you foresee any added benefit of triple agonist therapy (GLP-1, GIP and glucagon) for glycemic control in patients with Type 1 diabetes mellitus?
What patients with new onset diabetes require imaging of the pancreas?
How do you approach individualizing A1c goals in patients with dementia?
